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SUMMARY 
GABAA receptors (GABAARs) mediate neuronal inhibition in the brain. They are the primary targets 
for benzodiazepines, which are widely used to treat neurological disorders including anxiety, epilepsy 
and insomnia. The mechanism by which benzodiazepines enhance GABAAR activity has been 
extensively studied, but there is little mechanistic information on how non-benzodiazepine drugs that 
bind to the same site exert their effects. Eszopiclone and zolpidem are two non-benzodiazepine drugs 
for which no mechanism of action has yet been proposed, despite their clinical importance as sleeping 
aids. Here we investigate how both drugs enhance the activity of α1β2γ2 GABAARs. 
EXPERIMENTAL APPROACH 
Combining rapid ligand application onto macropatches and single-channel kinetic analysis, we show 
that both modulators slow current deactivation. This was confirmed in synaptic currents from primary 
neuronal cultures and heterosynapses, whereby native GABAergic nerve terminals form synapses onto 
HEK293 cells expressing α1β2γ2 GABAARs. Drug binding and modulation was quantified with the aid 
of an activation mechanism. 
KEY RESULTS 
At the single-channel level, the drugs prolonged the duration of receptor activations. The drugs exhibit 
similar Kd values of 80 nM and prolong channel activations primarily by increasing the equilibrium 
constant between two connected shut states that precede channel opening. 
CONCLUSIONS AND IMPLICATIONS 
As the derived mechanism successfully simulated the effects of eszopiclone and zolpidem on ensemble 
currents, we propose it as a definitive mechanism accounting for the effects of both drugs. Our findings 
reveal that eszopiclone and zolpidem enhance GABAAR currents via a mechanism that differs from 
that proposed for benzodiazepines. 
 
Abbreviations 
BZ, benzodiazepine; GABA, γ-aminobutyric acid; GABAAR, GABA type A receptor; HEK293, human 
embryonic kidney 293, IPSC, inhibitory post synaptic current. 
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INTRODUCTION 
γ-amino acid type A receptors (GABAARs) are selective targets for benzodiazepine (BZ-) binding site 
ligands, which have been used clinically for about 50 years to treat a range of neurological disorders 
including anxiety, epilepsy and insomnia. Heteromeric GABAARs are complexes of five subunits, 
usually composed of two α (α1-6), two β (β1-3) and a single γ (γ1-3), the most common arrangement 
being α1β2γ2. Other subunits have also been identified (δ, ε, π and ρ1-3). Each receptor incorporates a 
central, anion selective permeation pathway (Keramidas et al., 2004). Evidence gleaned from site-
directed mutagenesis suggests there is a single high affinity BZ-binding site, situated at the interface of 
α and γ subunits in the extracellular domain of each receptor (Berezhnoy et al., 2004; Rudolph et al., 
2011). This binding site is homologous to the two high affinity GABA binding sites found at the 
interfaces between β and α subunits (Rudolph et al., 2011). 
Mechanistic information drawn from investigations of classical BZs, such as diazepam, are all 
consistent with BZ-induced current enhancement, but vary with regard to the precise stage of the 
activation process that BZs perturb. This is partly due to the application of functional schemes that vary 
in the numbers and connections of discrete functional states (Campo-Soria et al., 2006; Gielen et al., 
2012; Li et al., 2013; Rogers et al., 1994; Rusch et al., 2005). In contrast to the numerous studies of 
classical BZs, scant mechanistic information exists for zolpidem and eszopiclone, which are 
structurally distinct from the classical BZs, but bind to the BZ site. 
Zolpidem and eszopiclone enhance GABAAR-mediated synaptic currents. Both induce sedation and 
hypnosis and are clinically important as treatments for sleep disorders (Darcourt et al., 1999; Krystal et 
al., 2003). Their molecular mechanisms of action have never been investigated in detail. The little 
information currently available suggests that zolpidem is a more potent modulator than eszopiclone of 
currents mediated by native α1β2γ2 GABAARs in mouse thalamocortical relay neurons (Jia et al., 
2009). However, in recombinant α1β2γ2 GABAARs expressed in X. laevis oocytes, estimates of the 
apparent affinities of the two drugs were similar, being 50-60 nM (Hanson et al., 2008). Zolpidem is 
reported to be highly selective for α1-containing GABAARs (Korpi et al., 2002; Wingrove et al., 2002), 
whereas the selectivity of eszopiclone remains uncertain. Finally, site-directed mutagenesis studies of 
residues in and around the BZ-binding pocket of α1β2γ2 GABAARs suggest the two modulators may 
bind in different orientations (Hanson et al., 2008) and enhance GABA-mediated currents via 
structurally different mechanisms (Morlock et al., 2011). The aim of the present study is to investigate 
GABAAR mediated current modulation by eszopiclone and zolpidem within the framework of a data-
derived activation mechanism that has previously been validated by us, and others (Dixon et al., 2014; 
Lema et al., 2006), with the addition of an explicit binding step for the modulator. 
 
METHODS 
Cell culture and transfections 
HEK293 cells were transfected with the cDNAs encoding the human α1 (pCIS2), β2 (pcDNA3.1+) and 
γ2S (pcDNA3.1+) subunits at a plasmid transfection ratio of 1α1:1β2:3γ2S, using a Ca2+ phosphate-
DNA co-precipitation method. CD4 or GFP were included as identifiers of transfected cells. To 
promote the formation of (co-culture) synapses between transfected HEK293 cells and primary rat 
cortical neurons, neuroligin 2A was also transfected. 
Electrophysiology 
All recordings were performed at room temperature (22 ± 1
oC) at a clamped potential of −70 mV, in 
whole-cell (synapses) or outside-out patch (single channel and macropatch) patch-clamp A
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configurations. The intracellular solution was composed of (in mM): 145 CsCl, 2 CaCl2, 2 MgCl2, 10 
HEPES, and 10 EGTA, adjusted to pH 7.4 with CsOH. The extracellular solution was componsed of 
(in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 D-glucose, adjusted to pH 7.4 with 
NaOH. 
Single channel and macropatch currents were recorded using an Axon 200B amplifier (Molecular 
Devices), filtered (3dB, 4-pole Bessel) at 5 kHz and sampled at 50 kHz. Synaptic currents were 
recorded using an Axon 700B amplifier, filtered at 4 kHz and sampled at 10 kHz. Currents were 
filtered offline to 5 kHz for making figures. 
Analysis 
Macropatch and synaptic currents were analysed using pClamp10 (Molecular Devices). 10-20 
macropatch currents were elicited from the same patch and averaged for measurement of rise and decay 
times. The rise and decay times from all patches were then averaged. Similarly, synaptic currents from 
each cell were selected, averaged for that cell and then combined with data from other cells to obtain 
total averages. Data represent group means ± SEMs. Group means were tested for significance using 
one-way ANOVAs and pair-wise comparisons were determined using Tukey’s test, where p<0.05 was 
taken as the significance threshold. For further detail on the analysis methods refer to supporting 
information. 
 
RESULTS 
Ensemble currents 
Two experimental approaches were employed to mimic the effects of 1 μM eszopiclone and zolpidem 
under synaptic conditions. The first set of experiments involved exposing excised outside-out patches 
to brief pulses of saturating GABA (±1 μM eszopiclone or zolpidem). The second involved quantitating 
the effect of both drugs on spontaneous and miniature IPSCs in HEK293-neuronal co-cultures and 
primary neuronal cultures, respectively. Three parameters were measured in these experiments: the 
peak current amplitude and the current activation and deactivation rates. 
Macropatches 
The effects of eszopiclone and zolpidem on macropatch currents were examined under two 
experimental conditions, which differed with respect to drug exposure time. In the first experiment, 
eszopiclone or zolpidem were co-applied with 5 mM GABA for ≤ 1 ms to naïve patches (Fig. 1A), 
whereas in the second experiment the patches were continuously perfused with drug for 1-2 minutes, 
prior to co-application with 5 mM GABA plus drug for ≤ 1 ms (Fig. 1B). The rational for these two 
experimental paradigms was to test if receptors could accumulate in modulator-bound states and affect 
currents. 
Current decay was quantified by fitting this phase of the current to two exponential components, 
then calculating the weighted time constant (Supporting information). Co-applying drug with GABA 
produced a slowing of current decay, with weighted time constants of 7.5 ± 0.6 ms for 5 mM GABA 
alone (n = 9), 12.4 ± 1.9 ms for eszopiclone (n = 9) and 15.6 ± 1.8 ms for zolpidem (n = 5). A one-way 
ANOVA indicated that both drugs had a significant effect on current decay (p<0.05), especially 
zolpidem (p<0.01, Figs. 1A, C). A similar effect was observed when the patches were pre-incubated 
with the drug for 1-2 minutes. The weighted time constants from these measurements were 12.3 ± 1.3 
ms for eszopiclone (n = 8) and 13.7 ± 1.5 ms for zolpidem (n = 12). Again, a one-way ANOVA 
indicated that both drugs significantly slowed current decay (p<0.05), with zolpidem having the greater 
effect (p<0.01, Figs. 1A, C). 
An analysis of the activation rate (see Supporting information) produced sub-millisecond activation 
time constants, which for the co-application experiments were 0.37 ± 0.04 ms (n = 9), 0.37 ± 0.02 ms 
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(n = 9) and 0.24 ± 0.03 ms (n = 5) for GABA alone, and co-application with eszopiclone or zolpidem, 
respectively. An ANOVA revealed that only zolpidem accelerated activation (p=0.044). A near 
identical pattern was observed for current activation when the recorded patches were first pre-incubated 
with either drug. The eszopiclone treatment produced an activation rate constant of 0.38 ± 0.04 ms (n = 
8) and for zolpidem the activation rate was 0.26 ± 0.02 ms (n = 12). Again, a significant increase in 
activation was only observed for zolpidem (p=0.030, Fig. 1D). 
The rapid, brief application of 5 mM GABA produced peak currents that ranged from 40-400 pA 
(mean, 148 ± 32 pA, n = 8). Co-applying or pre-incubating the patches with eszopiclone or zolpidem 
did not induce any statistically significant change (p<0.05) in peak amplitude (Fig. 1E). This is in 
accord with a report showing that zolpidem did not increase peak amplitude in rapid drug application 
onto macropatches when using saturating concentrations of GABA (Perrais et al., 1999). 
IPSCs in HEK293 cell co-cultures and primary neuronal cultures 
As eszopiclone and zolpidem affected macropatch currents mainly by slowing the decay rate, we 
wished to see if these drugs had comparable effects on α1β2γ2 GABAARs expressed in a more realistic 
synaptic context. As illustrated in the example recording in Fig. 2A, the effects of both drugs on 
spontaneous IPSCs (sIPSCs) mediated by recombinant α1β2γ2 GABAARs in HEK293 cells were 
observed within less than 10 s and were readily reversible. Upon perfusing the recorded cell with 
modulator a net increase in amplitude was observed (Fig. 2A, B). 
sIPSCs activated and decayed at rates that were similar to those of macropatch currents. The 
weighted deactivation time constant for spontaneous (drug free) currents was 9.2 ± 1.1 ms (n = 7). In 
the sustained presence of eszopiclone, the currents deactivated with a weighted time constant of 18.7 ± 
3.7 ms (n = 5) and for zolpidem the time constant was 15.5 ± 1.9 ms (n = 5, Fig. 2C, D). 
sIPSCs activated with a mean 10-100% activation time of 0.66 ± 0.04 ms (n = 7). In the presence of 
1 μM eszopiclone or zolpidem the currents activated with time constants of 0.56 ± 0.06 ms (n = 5) and 
0.60 ± 0.10 ms (n = 5), respectively, with no statistical difference between the three groups (p>0.05, 
Fig. 2E). The synaptic currents activated 2-fold more slowly than the macropatch currents, which may 
indicate that the concentration of GABA is lower at synapses than the 5 mM GABA that was used for 
the macropatch experiments. 
Unlike the negligible increase in macropatch recordings, both modulators increased the mean peak 
current. sIPSC peaks in the absence of drug ranged between 60-600 pA (mean, 166 ± 37 pA, n = 7). In 
the presence of eszopiclone, the peak current increased by 1.8 ± 0.1 -fold (n = 5), whereas zolpidem 
increased peak current by 2.6 ± 0.5 -fold (n = 5, Fig. 2A, F), both drugs producing statistically 
significant increases (p<0.05), especially zolpidem (p<0.01). 
To check whether the amplitude increase was due to enhanced neurotransmitter release, we tested 
the effects of both drugs on miniature IPSCs (mIPSCs). As mIPSCs could not be recorded with 
sufficiently high frequency from the heterosynapses, we recorded them from the cultured cortical 
neurons used in the heterosynapses (Fig. 3A, B). Control mIPSCs exhibited a mean decay time constant 
of 56.1 ± 2.6 ms (n = 4), which was greater than in the heterosynapses, possibly reflecting a more 
complex subunit expression in neurons. However, both drugs produced the expected increase in decay 
time constant, which was 76.8 ± 7.7 ms (n = 4) in eszopiclone and 102.2 ± 7.5 ms (n = 4) in zolpidem 
(Fig. 3C, D). These were significantly greater than control (p<0.05). mIPSCs from neurons had 10-
100% activation time constants similar to heterosynapses (0.65 ± 0.03 ms). Activation was unaffected 
by eszopiclone (0.65 ± 0.09 ms) or zolpidem (0.65 ± 0.04 ms). As predicted by our previous 
experiments, both drugs increased amplitude (control 61.3 ± 2.9 pA, eszopiclone 86.6 ± 6.5 pA, 1.4-
fold, zolpidem 95.7 ± 14.2 pA, 1.6-fold). The increases in decay times and peak amplitude were 
significant changes for both drugs (p<0.05). A
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As BZ-binding site ligands increase peak current elicited by subsaturating concentrations of GABA 
(Li et al., 2013; Morlock et al., 2011), the most likely explanation for the observed increase in peak 
current is that the net release of GABA at synapses is subsaturating, as has been postulated for some 
cortical GABAergic synapses (Perrais et al., 1999). Our ensemble current data suggest that the effects 
of both drugs are similar and occur upon rapid, brief exposure to the receptors. Since exposure times 
longer than 1 ms had no additional effect (Fig. 1A, B), our data provide no evidence for the 
accumulation of drug-bound receptors. 
 
Single channel currents 
Open and shut dwell times and open state occupancy (Po) 
The major effect of eszopiclone and zolpidem on macropatch currents was to decrease the decay rate 
without greatly affecting the activation rate or peak current. We next sought to investigate the 
mechanism that underlies the increased decay time via single channel kinetic analysis. Two key 
parameters of single channel currents were considered: the effect of drug on the duration of an 
activation, and the effect of drug on the relative time spent in open states within an activation (Po). Two 
converse experiments were carried out to measure these parameters. In the first, the concentration of 
drug was kept constant at 1 μM while varying the concentration of GABA, whereas in the second, the 
GABA concentration was maintained at 25 μM while the concentration of drug that was co-applied 
with GABA was either 5 or 20 μM. In addition to these measurements we monitored the open and shut 
dwell components obtained from fits to dwell histograms in the presence of GABA and drugs 
(Supporting information). Examples of single channel currents elicited by increasing GABA 
concentrations are shown in Fig. 4A. Preserving the three briefest shut components resulted in open 
dwell histograms with either three open (56% of patches) or two open (44% of patches) components. 
The presence of three shut components that are broadly similar over the concentration range (Fig. 4B) 
suggest that the that the majority of the activations are due to fully (di-) liganded receptors, even at 2 
μM GABA, consistent with other data (Keramidas et al., 2010; Lema et al., 2006; Macdonald et al., 
1989). At 5 mM GABA the fraction of the longest shut component decreased by over 9% compared to 
the mean of the other three concentrations (Fig.4B). The proportion of the longest open component 
increased by 2-fold as a function of GABA concentration (Fig. 4C). These small changes in dwell 
components, acting together are consistent with the modest increase in Po as a function of GABA 
concentration (Fig. 4D). Studies on glycine (Burzomato et al., 2004; Lape et al., 2008) and 
acetylcholine (Lape et al., 2008) receptors also show dwell components, that vary little (or very subtly 
as ours do) with agonist concentration and give rise to a sigmoidal Po-[agonist] trend. As illustrated by 
the group Po plots, a 1 μM concentration of either drug failed to have any effect on Po when co-applied 
with higher concentrations of GABA, although a moderate but significant increase in Po was seen at 2 
μM GABA (Fig. 4D). A modest, progressive increase in the Po was also observed as eszopiclone and 
zolpidem were increased from 5 to 20 μM, with zolpidem having a more prominent effect (Fig. 4E). 
Overall, the increase in Po was relatively small and similar for both modulators. 
Mean durations of single channel activations 
A greater effect of eszopiclone and zolpidem was seen in the durations of activations. Examples of 
these recordings for two GABA concentrations and 1 μM modulator are shown in Fig. 5A and the 
group data are shown plotted as a function of GABA concentration in Fig. 5B. At 2 μM GABA, 1 μM 
eszopiclone and zolpidem increased the mean activation duration from 29 ± 3 ms (GABA alone, n = 
11) to 51 ± 5 ms (n = 7) and 50 ± 4 ms (n = 8) for eszopiclone and zolpidem, respectively. This 
constitutes a 1.7-fold increase. Mean activation durations at 5 mM GABA were 160 ± 8 ms (n =14), 
which increased to 204 ± 7 (n = 5) ms and 211 ± 7 ms (n = 6) when 5 mM GABA was co-applied with 
1 μM eszopiclone or zolpidem, respectively, constituting a 1.3-fold increase. When 1 μM drug was co-
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applied with either 5 mM, 200 μM or 2 μM GABA the shut and open dwell components varied from 
those in GABA alone, with the same trend apparent for both drugs. The shortest shut components 
remained constant, whereas the second and third decreased and increased, respectively (Fig. 5C). There 
was an increase in all three open dwell time constants in the presence of either drug and the fractions of 
the first and second become nearly equal (Fig. 5D). 
Fixing the GABA concentration at 25 μM and varying the concentration of eszopiclone or zolpidem 
to 5 or 20 μM (Fig. 6A) also produced an increase in the durations of active periods per receptor. The 
mean activation duration for GABA alone was 71 ± 5 ms (n = 15), which increased in the presence of 5 
μM eszopiclone to 111 ± 6 ms (n = 8) and 20 μM eszopiclone to 109 ± 5 ms (n = 6). Exposing the 
patches to zolpidem produced similar increases in activation durations. 5 and 20 μM zolpidem 
increased activation duration to 108 ± 7 ms (n = 6) and 117 ± 7 ms (n = 4), respectively (Fig. 6B). An 
ANOVA performed on the drug treated groups indicated no significant difference in mean activation 
durations for both drugs at both 5 and 20 μM concentrations. These data indicate that the eszopiclone- 
and zolpidem-induced increase in the duration of activations saturates at 5 μM, and that both drugs 
enhance receptor activity via similar mechanisms. 
Consistent with our macropatch data, these results suggest rapid drug binding and provide no 
evidence for low affinity binding interactions between drug and the receptor. 
Activation mechanisms 
We recently derived a simple mechanism for activation by GABA using single channel currents from 
four synaptic GABAARs, including the α1β2γ2L receptor (Dixon et al., 2014), Fig. 7A). This 
mechanism had previously been validated at α1β2γ2S receptors (Lema et al., 2006). We re-examined 
this mechanism on α1β2γ2S GABAARs activated by GABA and modulated by the two benzodiazepine-
site ligands. We first used it to fit open and shut dwell histograms across a broad range of GABA 
concentrations, as previously described (Dixon et al., 2014; Keramidas et al., 2010). This enabled us to 
obtain state transition rate constants for the GABA binding and activation steps for this mechanism by 
maximum likelihood fitting (Colquhoun, 1995; Qin et al., 1997) (Table 1). The Kd for GABA was 119 
± 24 μM (n = 7 data sets, Table 2), similar to values previously derived for α1-containing GABAARs 
(Dixon et al., 2014; Lema et al., 2006). This scheme was then extended to include a single binding step 
for eszopiclone and zolpidem (Fig. 7B). This binding step was connected to either R, A1R, A2R
1
 or 
A2R
2
 separately, and fitted each time to data sets comprised of a series of open and shut dwell 
histograms (n = 3-4 for each modulator) that included data obtained at 1, 5 and 20 μM drug (Figs. 7C, 
D). During this fitting the binding steps for GABA were fixed to those previously determined (Kd = 
119 μM), but all other rate constants varied freely. A sequential decrease in the Kd for drug binding was 
observed when moving from left to right in the mechanism (Kd, R>A1R>A2R
1
>A2R
2
, Fig. 7B). Thus, 
the two highest affinities were for A2R
1
 and A2R
2
. However, A2R
2
 was rejected as a candidate for drug 
binding because it produced current simulations that deactivated too slowly relative to the recorded 
currents (see below), whereas R and A1R were rejected because corresponding simulated currents were 
exceedingly fast. When the modulator binding step was connected to A2R
1
 the Kds for eszopiclone and 
zolpidem were calculated to be 83 ± 7 nM and 76 ± 9 nM, respectively (Table 1). Other equilibrium 
constants that notably changed downstream of the binding reaction was Φ (φ’1/φ’−1), which increased 
from 1.2 for GABA alone to 2.2 and 2.4 for eszopiclone and zolpidem, respectively, in both cases the 
change was significantly different from GABA alone. A comparable inference was made for the same 
receptors in the presence of diazepam, where an increase in the equilibrium constant between two 
postulated shut states that preceded channel opening was sufficient to recapitulate a diazepam-induced 
shift in the concentration-response relationship (Gielen et al., 2012). Our analysis revealed that both 
modulators also consistently increased Σ (1/−1) and decreased E3 (3/3) (Table 2). However, the 
effects on Σ and E3 were relatively minor and failed to reach significance. A
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Ensemble current simulations 
Our derived mechanisms for activation by GABA alone, and modulation by eszopiclone and zolpidem 
were used to simulate ensemble macropatch currents. The activation and deactivation time constants 
were then compared to those of the corresponding recorded currents, and thereby acted as an 
independent validation of the mechanisms (Dixon et al., 2014; Kienker, 1989). The activation 
mechanism for GABA alone produced a simulated current that activated with a time constant of 0.5 ms 
and deactivated with two exponential components with a weighted average of 9.0 ms. These compare 
well with the recorded values (Fig. 8A), suggesting our mechanism, together with rate constants, 
provides a good description of α1β2γ2S GABAAR activation by GABA. A similar procedure was 
carried out for current modulation by eszopiclone and zolpidem. The mechanism used for these 
simulations included the high affinity binding step for the modulator, leading to GABA- and 
modulator-bound states. The eszopiclone-modulated simulation produced a current that activated with a 
10-100% rise time constant of 0.4 ms and deactivated with a weighted time constant of 14 ms (Fig. 
8B). Similarly, the zolpidem-modulated current simulation produced parameters for activation and 
weighted deactivation that were, 0.4 ms and 15 ms, respectively (Fig. 8C). The quantitative likeness 
between simulations and recorded currents suggests that the simple mechanism used here is a suitable 
descriptor of activation and modulation of GABAARs by BZ-site modulators. 
DISCUSSION & CONCLUSIONS 
As with traditional BZs, zolpidem and eszopiclone work by enhancing GABAergic inhibitory drive. 
Here we have identified two mechanisms by which they achieve this. Our macropatch results indicate 
that they potentiate ensemble currents by slowing the deactivation phase. This occurs rapidly, as 
indicated by the similarity between brief (1 ms) and longer (1-2 min) drug applications onto 
macropatches. Indeed, exposing the receptors to either drug for several minutes in the heterosynapse 
and primary culture experiments resulted in a similar increase in current decay times. In addition, our 
results from sIPSCs and mIPSCs show that they not only slow the decay of GABAergic inhibitory 
postsynaptic currents via a direct action on the postsynaptic GABAARs, they also increase the 
magnitude of GABAergic synaptic currents, an observation also made for zolpidem on cortical neurons 
(Perrais et al., 1999). This later effect could be because GABA release at some synapses is 
subsaturating. As zolpidem and eszopiclone appear to achieve these effects via identical mechanisms 
and similar potencies at the α1β2γ2 GABAAR, their differing therapeutic profiles must be due to either 
different pharmacological effects at other central nervous system receptors (Jia et al., 2009; Nutt et al., 
2010), or to different pharmacokinetic or distribution profiles. 
On the level of a single GABAAR, potentiation was manifested mainly as an increase in the duration 
of activations. An increase in the open state occupancy was also detected at low GABA concentrations, 
as also reported for diazepam (Li et al., 2013). The duration of an active period is a key functional 
property of a channel, and it is this property that correlates with decay times in ensemble currents 
(Dixon et al., 2014; Wyllie et al., 1998). Although the lowest GABA concentration used here to elicit 
activations was likely too high (2 μM, activation duration 30 ms), estimates of the minimum 
activation duration (7−10 ms) (Keramidas et al., 2006; Macdonald et al., 1989) is a much closer 
match to the decay times of the ensemble currents measured here. We utilized a simple activation 
mechanism that incorporates six fully liganded states to determine how the BZ-binding site ligands 
might induce longer single channel activations. GABA and drug concentrations that GABAARs at 
native synapses would be exposed to were used in the experiments. Our scheme omits un- and mono-
(GABA) liganded open and shut states, due to the similarity in the shut dwell time analysis across 
GABA concentrations (Keramidas et al., 2010; Lema et al., 2006), which indicated that the vast 
majority of activations arose from fully liganded receptors. However, we acknowledge that below 2 
μM GABA there may be some contribution from mono-liganded receptors to the overall activity 
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(Macdonald et al., 1989), and that un-liganded openings, although possible (Colquhoun et al., 2012), 
would be exceedingly rare at the GABA concentrations used here. The mechanism facilitated an 
estimation of the Kd for each modulator. Our analysis suggests that both modulators bind the receptor 
with similar affinities (Kds  80 nM), similar to estimates obtained from radio-ligand binding 
experiments (Hanson et al., 2008). In contrast to mutagenesis studies that suggest that there are some 
structural differences that mediate potentiation between zolpidem and eszopiclone (Morlock et al., 
2011), our study suggests that on a functional level these two modulators are equivalent. This could 
occur if the net work (energy changes) done by zolpidem and eszopiclone on the receptor is similar and 
independent of the structural details of the ligand and binding site residues (Purohit et al., 2014). This 
inference is supported by the similar Kds for both modulators, which is a function of the energy of 
binding. 
In a previous study using the same activation mechanism employed here, we reported that channels 
with a higher affinity for GABA remain active for longer (Dixon et al., 2014). Here, we further report 
that by promoting the transition between two connected, fully liganded shut states (Φ) that precede 
channel opening, the activations of a single channel can also be increased. An increase in the 
equilibrium constant between two pre-conducting states has also been inferred by fitting diazepam 
concentration-response data with a simple, linear mechanism on the same GABAARs (Gielen et al., 
2012). This is in contrast to the conclusions of all other studies that have investigated the mechanisms 
of BZ-induced current enhancement. BZs have generally been modelled as increasing the receptor 
affinity for GABA (Rogers et al., 1994) or the receptor ‘gating’ efficacy (the final shut-to-open 
transition) (Campo-Soria et al., 2006; Li et al., 2013; Rusch et al., 2005). Crucial differences between 
other studies and ours is that our single channel and ensemble currents were best described by an 
activation mechanism that contains two connected shut states that immediately follow ligand binding, 
and that a discrete binding step for drug was appended to the scheme. Our results are qualitatively 
similar to those of Gielen et al., albeit with a smaller increase in the pre-conducting transition 
equilibrium constant. However, our data are also described by a more complex data-derived activation 
mechanism, based on single channel analysis. Recording from single GABAARs also enabled us to 
directly demonstrate the corresponding functional outcome of increasing Φ. The slightly higher Φ 
value for zolpidem is consistent with a marginally faster activation rate in macropatch currents. 
Although we found no significant changes in Σ and E3, both drugs affected these constants in the same 
manner. Other studies identify the shut state associated with Σ as a fast desensitized receptor state 
(Jones et al., 1995). The observed increase in the duration of activations in the presence of both drugs 
is also consistent with a reduced occupancy of the receptor in desensitized states. 
Structurally, Φ could represent a concerted movement of all subunits, as has been demonstrated for 
glycine and acetylcholine receptors (Burzomato et al., 2004; Lape et al., 2008) or two, independent 
binding site-specific structural changes that are each linked to channel opening in the acetylcholine 
receptor (Mukhtasimova et al., 2009). These function-based investigations are consistent with local 
binding site structural changes that do not affect the initial encounter affinity (Kd) for the agonist, but 
rather underlie the structural switch to a higher affinity state associated with an activated receptor 
(Purohit et al., 2013; Purohit et al., 2014). In addition, these studies suggest that for agonists that bind 
orthosteric sites, such as acetylcholine and GABA, direct communication between binding sites is not 
required for receptor activation. For modulators such as zolpidem and eszopiclone that bind to a site 
that is homologous to the orthosteric site, we find that, here too, the current enhancing effects can be 
wholly accounted for with a constant Kd for GABA. This essentially rules out direct communication 
between the GABA and zolpidem/eszopiclone binding sites as a candidate for Φ. High-resolution 
structures of pLGICs suggest that agonist binding triggers the inner β-sheet of the extracellular domain 
to rotate while simultaneously tilting the outer β-sheet upwards to close a critical binding site element 
(loop C) around the bound agonist (Bocquet et al., 2009; Hilf et al., 2009). These movements are then A
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transmitted to the pore-lining, second (M2) of four transmembrane domains via a differential 
movement of loops 2 and 7 (both part of the inner β-sheet) and the β10-M1 domain, which is linked to 
the outer β-sheet. 
Alternately, Φ may represent a conformational change restricted to the interface of the ligand 
binding and transmembrane domains (LBD-TMD). For example, in the α1 homomeric glycine receptor 
(GlyR) the magnitude of a conformational change reported by a label attached to a residue on loop 2 
(α1A52C) was correlated with agonist efficacy (Pless et al., 2009). This suggests that Φ corresponds to 
an agonist-specific conformational change at the LBD-TMD interface. This is supported by an earlier 
study showing that the α1A52S mutation specifically alters Φ in the same GlyR (Plested et al., 2007). 
Moreover, combined crystallography and functional analyses suggest Φ may correspond to a ‘locally 
closed’ conformation whereby all receptor domains reside in the activated state with exception of M2 
(Prevost et al., 2013; Prevost et al., 2012). As this state involves loop 2 and the M2-M3 linker adopting 
a specific conformation relative to each other, it supports the idea of Φ involving an agonist-specific 
conformational change at the LBD-TMD interface (Pless et al., 2009; Plested et al., 2007). 
As a crucial step in the development of new therapeutics, it is important to have a quantitative 
understanding of how therapeutic drugs bind to GABAARs and modulate their activity. A universal 
mechanism for modelling GABAAR activation and modulation by endogenous and synthetic 
compounds would facilitate this. Our mechanism may be suitable as a starting point. This mechanism 
has now been tested on several synaptic GABAARs (Dixon et al., 2014; Lema et al., 2006), where it 
successfully accounts for single channel and ensemble currents, including those modulated by 
eszopiclone and zolpidem. 
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Table 1. Rate constants for activation scheme 
 
GABA 
k+1 k−1 1 −1 1 −1 1 1 2 2 3 3 
3.2 ± 
0.8
#
 
380 ± 
38 
1110 
± 55 
933 ± 
73 
143 ± 
55 
348 ± 
106 
955 ± 
70 
1911 
± 165 
256 ± 
66 
747 ± 
103 
961 ± 
185 
912 ± 
146 
GABA + eszopiclone 
ψ1 ψ−1 1’ −1’ 1’ −1’ 1’ 1’ 2’ 2’ 3’ 3’ 
9.7± 
0.6
$
 
8.0 ± 
4.0 
1802 
± 54 
812 ± 
32 
223 ± 
42 
351 ± 
4 
920 ± 
59 
1972 
± 137 
260 ± 
43 
793 ± 
29 
950 ± 
80 
1011± 
38 
GABA + zolpidem 
ψ1 ψ−1 1’ −1’ 1’ −1’ 1’ 1’ 2’ 2’ 3’ 3’ 
9.9 ± 
0.5
#
 
7.5 ± 
6.0 
1816 
± 330 
752 ± 
209 
206 ± 
38 
362 ± 
13 
923 ± 
180 
2008 
± 180 
243 ± 
177 
755 ± 
54 
934 ± 
59 
1101 
± 56 
Rate constants for state transitions related to the schemes in Fig. 7. 
#
x10
6
, 
$
x10
7
. 
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Table 2. Equilibrium constants 
 
GABA 
Kd-G (μM) Φ Σ E1 E2 E3 
119 ± 24 1.2 0.4 0.5 0.3 1.1 
GABA + eszopiclone 
Kd-E (nM) Φ’ Σ’ E1’ E2’ E3’ 
83 ± 7 2.2 0.6 0.5 0.3 0.9 
GABA + zolpidem 
Kd-Z (nM) Φ’ Σ’ E1’ E2’ E3’ 
76 ± 9 2.4 0.6 0.5 0.3 0.8 
Equilibrium constants calculated from Table 1. Kd-(G)ABA (k−1/k+1), Kd-E or-Z (ψ−1/ ψ+1), Φ (1/−1), 
Σ (1/−1), E1 (1/1), E2 (2/2), E3 (3/3). 
 
FIGURE LEGENDS 
 
Figure 1. Macropatch currents mediated by α1β2γ2S GABAARs in response to GABA, 
eszopiclone and zolpidem. A. Sample recordings of macropatch currents in response to  1 ms (arrow 
head) application of 5 mM GABA (black) or co-application of 5 mM GABA and 1 μM eszopiclone 
(green) or zolpidem (blue). An expanded view of the activation phase of the currents, along with the 
10-100% fits (red) is shown as an inset B. Macropatch recordings in response to  1 ms (arrow head) 
application of 5 mM GABA (black) or co-application of 5 mM GABA and 1 μM eszopiclone (green) 
or zolpidem (blue) after 1-2 minutes pre-incubation of the test drug. Note the comparable slowing of 
current decay for both drugs in A and B. Each current trace in A and B represents an average of 10-20 
recordings from the same patch. C. Group averages of current deactivation rates showing a significant 
slowing in the presence of 1 μM eszopiclone and zolpidem. D. Group averages of the activation rates 
of macropatch currents in the presence of 1 μM eszopiclone and zolpidem. No significant change in 
activation rates was observed in the presence of either drug E. Averaged data of the change in peak 
current upon exposure to 1 μM eszopiclone and zolpidem. Neither drug produced any significant 
change in peak current. Currents were recorded at a holding potential of −70 mV. * p<0.05. 
 
Figure 2. sIPSCs in heterosynapses between neurons and HEK293 cells expressing α1β2γ2S 
GABAARs. A. A whole-cell recording of sIPSCs in the presence and absence of 1 μM eszopiclone or 
zolpidem. The effects of both drugs were completely reversed within seconds of drug washout. B. 
Expanded view of segments of record in A showing that both modulators increased mean peak 
amplitude. C. Averaged (typically from 10-20 individual sIPSCs), normalized synaptic currents in the 
absence of drug (black) or presence of 1 μM eszopiclone (green) or zolpidem (blue) showing that both 
drugs decreased the decay rate of the synaptic currrents. D. Averaged data for the deactivation rate of 
synaptic currents showing the both drugs significantly slowed this phase of the current. * p<0.05. E. 
Averaged data of the activation rate of synaptic currents showing that neither drug had any effect on 
current activation. F. Averaged, normalized peak synaptic currents showing that both drugs enhance 
current amplitude (p<0.05). 
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Figure 3. mIPSCs in primary neuronal cultures. A. Neuronal mIPSCs in the presence and absence 
of 1 μM eszopiclone or zolpidem. To isolate mIPSCs, the experiments were conducted in the presence 
of TTX (200 nM), CNQX (10 μM) and AP5 (50 μM). B. Expanded view of segments of record in A. 
C. Averaged and normalized mIPSCs in the absence of drug (black) or presence of 1 μM eszopiclone 
(green) or zolpidem (blue). D. Averaged data for the deactivation rate of mIPSCs showing the both 
drugs significantly slowed this phase of the current. * p<0.05. E. Averaged data of the activation rate of 
synaptic currents showing that activation was unaffected by either durg. F. Averaged, normalized peak 
synaptic currents showing that both drugs enhance current amplitude (p<0.05). 
 
Figure 4. Eszopiclone and zolpidem have modest effects on single channel open probability. A. A 
series of single channel recordings, showing that single channel activations increase in duration and 
intra–activation open probability with increasing GABA concentration. Examples of activations are 
indicated by a grey horizontal bar and shown in expanded view directly below each trace for each 
concentration. B and C. Scatter plots of shut and open dwell components as a function of concentration 
of GABA. The corresponding fractions are shown in parentheses next to each data point. D. Group 
concentration-response plot showing an increase in intra–activation open probability as a function of 
GABA concentration. 1 μM eszopiclone or zolpidem had no detectable affect on Po at high GABA 
concentrations. A modest increase in Po was seen at 2 μM GABA. The data for GABA alone were fit to 
a Hill type equation. E. The effect on PO with increasing concentrations of modulator. The 
concentration of GABA was kept constant at 25 μM for these experiments. Zolpidem was modestly 
more potent at increasing Po than eszopiclone. 
 
Figure 5. Eszopiclone and zolpidem increase the active periods of single channel currents. A. 
Single channel recording at 2 μM and 200 μM GABA and 1 μM zolpidem (above) and eszopiclone 
(below). The upper and lower pairs of traces were recorded from the same patch to control for channel 
number. Note that both drugs increased the durations of active periods. B. Group concentration-
response plot showing the effects on active period durations in the presence of 1 μM eszopiclone 
(green) and zolpidem (blue) as a function of GABA concentration. The plot for GABA alone was fit to 
a Hill type equation. C and D. Scatter plots of shut and open dwell components in the presence of 1 μM 
zolpidem or eszopiclone. The corresponding fractions for each time constant are shown in parentheses. 
 
Figure 6. Eszopiclone and zolpidem effects on activation durations saturates at low μM 
concentrations. A. Single channel currents elicited by 25 μM GABA followed by co-application of 25 
μM GABA plus 20 μM zolpidem (above) or 5 μM eszopiclone (below). Each pair of recordings was 
obtained from the same patch. B. Group plot showing that both modulators increase in the duration of 
active periods with similar potency, which saturate at 5 μM drug. 
 
Figure 7. Mechanisms for activation and modulation of α1β2γ2S GABAARs. A. A mechanism for 
activation by GABA, where, A is the agonist and R is the receptor. A1R and A2R denotes a singly and 
doubly liganded receptor, respectively. The superscripted numbers denote the state number and the 
asterisk denotes open, conducting states (red). The symbols above and below the double arrows that 
connect states are the rate constants for the forward and backward transitions. B. The same activation 
mechanism as in A with a single binding step for modulator (eszopiclone or zolpidem) leading to 
GABA bound and modulator bound (Ω) states. Modulator-bound open states are shown in orange. 
When the binding step for modulator was appended to the grey states the mechanism did not 
successfully simulate ensemble currents. An accurate fit to single channel and ensemble currents was 
achieved when the modulator was appended to A2R
1
. The scheme used for the simulations is shown in 
black C. Examples of data sets that were used to determine the rate and zolpidem binding constants in A
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the mechanism shown in B. D. Examples of data sets that were used to determine the rate and 
eszopiclone binding constants in the mechanism shown in B. Note that scheme was fitted (maximum 
likelihood) to open and shut dwell components of the data shown in C and D to optimize the 
corresponding rate constants. 
 
Figure 8. Recorded and simulated ensemble currents. A. Ultra-fast application of saturating GABA 
(5 mM) produces a rapidly developing current (0.4 ms) that decays with a weighted time constant of 8 
ms (left). Using the mechanism shown in Fig. 6A along with the rate constant in Table 1 generates a 
simulated macropatch current with similar activation and decay times (right). B. A macropatch current 
recorded in the presence of eszopiclone (left). The mechanism shown in Fig. 6B, along with 
corresponding rate constants in Table 1 generates a simulated ensemble current (right) that is similar to 
the recorded current. C. A macropatch current recorded in the presence of zolpidem (left). As for 
eszopiclone, the mechanism shown in Fig. 6B, together with corresponding rate constants generates a 
simulated ensemble current (right) that is similar to the recorded current. 
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